Cerus Corp (CERS) FinancialsCERSFinancialCerus Corp

Cerus Corp (CERS) generates its revenue primarily from Product, which accounts for 100.0% of total sales, equivalent to $57.44M. Understanding this concentration is critical for investors evaluating how CERS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Cerus Corp maintains a gross margin of 55.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.94%, while the net margin is -4.71%. These profitability ratios, combined with a Return on Equity (ROE) of -10.81%, provide a clear picture of how effectively CERS converts its operational activities into shareholder value.

In the context of the broader market, CERS competes directly with industry leaders such as TCMD and DCTH. With a market capitalization of $548.15M, it holds a significant position in the sector. When comparing efficiency, CERS's gross margin of 55.91% stands against TCMD's 75.50% and DCTH's 89.75%. Such benchmarking helps identify whether Cerus Corp is trading at a premium or discount relative to its financial performance.

Cerus has shown strong revenue growth, with Q2 2026 revenue of $63.3 million, a 5.3% increase year-over-year, and a guidance upgrade for 2026 product revenue to $229 million to $231 million, indicating confidence in future sales.